OnkoSight Exon Coverage

Exon Coverage

OnkoSight panels are targeted assays that are meant to be highly actionable and reduce the number of unclear variant results. To that end, coverage of the genes included on OnkoSight panels has been carefully selected based on the actionable mutations recommended in established national guidelines and published literature.

ONKOSIGHT MYELOID DISORDER PANEL

GENEEXON COVERED
ABL14, 5, 6
ASXL112
BCOR2-15
BCORL11-12
BRAF15
CALR9
CBL8, 9
CDKN2A1, 2
CSF3R14-17
DNMT3A2-23
ETV61-8
EZH22-20
FBXW79-11
FLT313-15, 20
GATA22-4, 6
HRAS2, 3
IDH14
IDH24
JAK212, 14
KIT2, 8-11, 13, 17
KRAS2, 3
MPL10
MYD883-5
NPM111
NRAS2, 3
PHF62-10
PTEN5, 7
PTPN113, 13
RUNX12-9
SETBP14
SF3B113-16
SRSF21
TET23-11
TP532-11
U2AF12, 6
WT17, 9
ZRSR21-11

ONKOSIGHT SOLID TUMOR PANEL

GENEEXON COVERED
AKT13
ALK20, 22-25
BRAF11 and 15
CTNNB13
DDR25, 8, 13, 15, 17
EGFR7, 12, 15, 18-21
EPHA25
ERBB219-21
ESR17, 9, 10
FGFR15, 8
FGFR27, 9, 12
FGFR37, 9, 14, 18
GNA115
GNAQ5
HRAS2, 3
IDH14
IDH24
KIT9, 11, 13, 14, 17, 18
KRAS2, 3, 4
MAP2K12, 3, 6
MET2, 14, 16, 19
MTOR44, 53
NOTCH126
NRAS2, 3, 4
PDGFRA12, 14, 15, 18
PIK3CA2, 3, 6, 10, 21
PTEN9-2
RAC12
RET10, 11, 13, 15, 16
ROS138
TP532, 4-11

Next-generation sequencing provides increased gene coverage compared to other testing methods, such as PCR. OnkoSight panels include the latest actionable biomarkers, improving coverage across genes like EGFR, KRAS, and NRAS.

Onkosight Coverage:
EGFR:
Targeted PCR Coverage:
EXON 12
EXON 15
EXON 18
EXON 19
EXON 20
EXON 21